World BI is again organizing a conference on Drug Discovery Innovation Programme, 8-9 September, 2027 in Basel, Switzerland.
A move toward creating medications that can target previously difficult biological pathways is reflected in the increased interest in RNA therapies drug discovery 2027. Scientists are progressively choosing the modality that best fits the disease process rather than concentrating on a single RNA method.
Why RNA Therapeutics are Expanding
RNA provides a compelling means of influencing the molecular and genetic aspects of disease biology. Researchers are able to overcome some of the obstacles that previously hindered the development of RNA-based drugs because to developments in delivery systems, chemical modification, and computational design.
This expansion is being driven primarily by:
- siRNA: Designed to promote the breakdown of targeted messenger RNA in order to silence particular genes.
- Antisense oligonucleotides: brief synthetic sequences that can change splicing, disrupt RNA processing, or decrease the synthesis of proteins linked to disease.
- RNA-targeting discovery: Researchers are now able to identify and modify RNA molecules that are relevant to disease thanks to new methods.
- Emerging RNA modalities: Scientists are looking on new approaches that might increase RNA's therapeutic potential beyond traditional mRNA uses.
Emerging RNA Modalities Beyond mRNA
RNA therapeutics are expanding well beyond mRNA vaccines. The 2026 review highlights siRNA, antisense oligonucleotides (ASOs), miRNA, aptamers, and CRISPR–Cas-related approaches as important platforms for regulating gene expression and addressing disease at the molecular level. Advances in delivery technologies are also improving the therapeutic potential of these modalities.
The field is now moving toward newer non-coding RNA modalities, including circular RNAs (circRNAs), long non-coding RNAs, small nucleolar RNAs, and tRNA-derived fragments. These approaches could offer new ways to regulate gene activity, RNA processing, and protein production. However, challenges such as: tissue-specific delivery, off-target effects, immunogenicity, and scalable manufacturing still need to be addressed.
siRNA and ASOs in Drug Discovery
Selectively lowering the expression of a gene linked to a disease can lead to therapeutic prospects, as shown by the creation of siRNA drug discovery platforms. Researchers are also able to investigate new tissues and targets thanks to advancements in conjugation technology and delivery methods.
However, because antisense oligonucleotides can interact with RNA in a variety of ways, they continue to draw interest.
Because of their adaptability, oligonucleotide therapies are especially intriguing for conditions where traditional small molecules or antibodies might not be able to reach the intended target.
What Comes Next?
Future RNA modes beyond mRNA will probably depend on resolving a number of real-world issues:
- Enhancing the delivery of tissue-specific.
- Improving durability and stability.
- Lowering undesired immunological reactions.
- Finding appropriate RNA targets.
- Increasing the scalability and affordability of manufacturing.
RNA-based methods may be incorporated more frequently into standard drug discovery processes as these technologies advance.
Conclusion
By 2027, the field of RNA therapy will be far more expansive than that of mRNA. Emerging RNA-targeting techniques, antisense oligonucleotides, and siRNA are opening up new avenues for tackling challenging biological targets.
Researchers and drug makers have the chance to learn which RNA modality is most appropriate for a given illness mechanism rather than just finding another RNA medication. RNA therapies may play a bigger role in the upcoming generation of drug discovery as delivery, chemistry, and target identification continue to advance.
World BI Drug Discovery Innovation Programme
The Drug Discovery Innovation Programme organized by World BI is a leading global event that brings together pharmaceutical executives, researchers, biotech innovators, and technology experts to explore the latest advancements in drug discovery and early development.
Organized by World BI, the conference focuses on key topics such as AI-driven drug discovery, target identification, precision medicine, biomarker development, computational drug design, and emerging therapeutic modalities. The programme provides a collaborative platform for industry leaders to share insights, address challenges, and accelerate the development of innovative therapies that improve patient outcomes worldwide.